Brought to you by Investec Switzerland. Roche Holding AG said its most advanced experimental drug to harness the immune system in the fight against cancer may win U.S. regulatory approval this year, becoming the first such treatment to help the roughly 430,000 people diagnosed annually with bladder cancer. The medicine, called atezolizumab, may generate around $3 […]
Roche cancer drug too expensive for UK’s National Health Service (NHS)
Brought to you by Investec Switzerland. The UK’s National Institute for Health and Care Excellence (NICE), says Roche’s breast cancer drug Kadcyla is still too expensive. Although retained for use through the Cancer Drugs Fund, Roche’s breast cancer treatment, Kadcyla (trastuzumab emtansine), will not be recommended for routine NHS use because its price remains too high. NICE’s draft […]
SMI up, Roche up, Watch exports slump, Bank capital increases demanded
23 October 2015 – Weekly Swiss and global market roundup. Brought to you by Investec Switzerland. Swiss financial market news Global stocks rallied after “Super Mario” signaled that additional monetary stimulus is on the table if growth continues to falter. The SMI outperformed global stocks after it received a further lift from hints that Europe […]
Switzerland opens its tallest building
Last Friday saw the opening of Switzerland’s tallest building. The 41 level, 178 metre high tower is the first of two to grace the skyline of Basel. Building 1, as it is quite logically named, was designed by the Swiss architectural firm Herzog & de Meuron for the pharmaceutical giant Roche. It is 52 metres […]